Drug Database
Back to search

Netherlands· NL-ebcf3ec14da3

Tybost 150 mg filmomhulde tabletten

A cobicistat product containing cobicistat, registered in Netherlands by Gilead Sciences Ireland UC. The same ATC class is registered in 9 of our 19 countries.

ATC V03AX03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTybost 150 mg filmomhulde tablettenATCV03AX03REGISTER NO.NL-ebcf3ec14da3PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cobicistatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cobicistat is registered in 9 of 19 countries.

Countries holding a registration under ATC V03AX03 (cobicistat), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search cobicistat products by name

Cobicistat · ATC V03AX03

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
COBICISTAT
Manufacturer
Gilead Sciences Ireland UC
Country
Netherlands (NL)
ATC code
V03AX03
ATC class
Cobicistat
Defined daily dose
0.15 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/13/872

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

541 interactions on record for cobicistat.

Graded by severity as the source publishes them — 243 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cobicistat against other medicinesHow interaction checks work

Cobicistat · interactions on record

541 records

  • 243 severe
  • 277 moderate
  • 21 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • LoperamideA07DA03severe
  • EluxadolineA07DA06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cobicistat in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cobicistat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tybost
  • Liechtenstein · Tybost
  • Norway · Tybost

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/97102376-4e4c-457b-8c29-3b4cacc51e17
GET /v1/drugs/97102376-4e4c-457b-8c29-3b4cacc51e17?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tybost-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cobicistat",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp112218",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE GEEL (E 172)",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "ZONNEGEEL FCF ALUMINIUMLAK (E 110)"
  ],
  "substances": [
    "COBICISTAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2013/09/19",
  "procedure_number": "EMEA/H/C/002572",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/872",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about cobicistat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console